Cost–Effectiveness of Pharmacogenetic-Guided Dosing of Phenprocoumon in Atrial Fibrillation

• Ansell J , HirshJ, PollerL, BusseyH, JacobsonA, HylekE. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest126(Suppl. 3) , S204–S233 (2004).
   PubMed Web of Science ®Google Scholar
• Ansell J , HirshJ, HylekE, JacobsonA, CrowtherM, PalaretiG. Pharmacology and management of the vitamin K antagonists: American College of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest133(Suppl. 6) , S160–S198 (2008).
   PubMed Web of Science ®Google Scholar
• Pengo V , PegoraroC, CucchiniU, IlicetoS. Worldwide management of oral anticoagulant therapy: the ISAM study. J. Thromb. Thrombolysis21(1) , 73–77 (2006).
   PubMed Web of Science ®Google Scholar
• Schalekamp T , de Boer A. Pharmacogenetics of oral anticoagulant therapy. Curr. Pharm. Des.16(2) , 187–203 (2010).
   PubMed Web of Science ®Google Scholar
• Rosendaal FR . The scylla and charybdis of oral anticoagulant treatment. N. Engl. J. Med.335(8) , 587–589 (1996).
   PubMed Web of Science ®Google Scholar
• Merli GJ , TzanisG. Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio? J. Thromb. Thrombolysis27(3) , 293–299 (2009).
   PubMed Web of Science ®Google Scholar
• Wysowski DK , NourjahP, SwartzL. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch. Intern. Med.167(13) , 1414–1419 (2007).
   PubMed Web of Science ®Google Scholar
• Torn M , CannegieterSC, BollenWL, van der Meer FJ, van der Wall EE, Rosendaal FR. Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. Arch. Intern. Med.169(13) , 1203–1209 (2009).
   PubMedGoogle Scholar
• Bodin L , VerstuyftC, TregouetDA et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106(1) , 135–140 (2005).
   PubMed Web of Science ®Google Scholar
• Wadelius M , ChenLY, LindhJD et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4) , 784–792 (2009).
   PubMed Web of Science ®Google Scholar
• Consortium IWP , KleinTE, AltmanRB et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8) , 753–764 (2009).
   PubMed Web of Science ®Google Scholar
• van Schie RM , WesselsJA, le Cessie S et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur. Heart J.32(15) , 1909–1917 (2011).
   PubMed Web of Science ®Google Scholar
• Anderson JL , HorneBD, StevensSM et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116(22) , 2563–2570 (2007).
   PubMed Web of Science ®Google Scholar
• Hillman MA , WilkeRA, YaleSH et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin. Med. Res. 3(3) , 137–145 (2005).
   PubMedGoogle Scholar
• Caraco Y , BlotnickS, MuszkatM. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin. Pharmacol. Ther.83(3) , 460–470 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson JL , HorneBD, StevensSM et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125(16) , 1997–2005 (2012).
   PubMed Web of Science ®Google Scholar
• van Schie RM , WadeliusMI, KamaliF et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10(10) , 1687–1695 (2009).
   PubMed Web of Science ®Google Scholar
• French B , JooJ, GellerNL et al. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 11 , 108 (2010).
   PubMed Web of Science ®Google Scholar
• Do EJ , LenziniP, EbyCS et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J. 12(5) , 417–424 (2012).
   PubMed Web of Science ®Google Scholar
• Meckley LM , GudgeonJM, AndersonJL, WilliamsMS, VeenstraDL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics28(1) , 61–74 (2010).
   PubMed Web of Science ®Google Scholar
• Schalekamp T , BoinkGJ, VisserLE, StrickerBH, de Boer A, Klungel OH. CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? Clin. Pharmacol. Ther.79(6) , 511–520 (2006).
   PubMed Web of Science ®Google Scholar
• Fang MC , GoAS, ChangY et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am. J. Med. 120(8) , 700–705 (2007).
   PubMed Web of Science ®Google Scholar
• Rosendaal FR , CannegieterSC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost.69(3) , 236–239 (1993).
   PubMed Web of Science ®Google Scholar
• Oake N , JenningsA, ForsterAJ, FergussonD, DoucetteS, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ179(3) , 235–244 (2008).
   PubMed Web of Science ®Google Scholar
• Howard R , LeathartJB, FrenchDJ et al. Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon(R) probes. Clin. Chim. Acta 412(23–24) , 2063–2069 (2011).
   PubMed Web of Science ®Google Scholar
• Struijs JN , van Genugten ML, Evers SM, Ament AJ, Baan CA, van den Bos GA. Future costs of stroke in The Netherlands: the impact of stroke services. Int. J. Technol. Assess. Health Care22(4) , 518–524 (2006).
   PubMed Web of Science ®Google Scholar
• Verhoef TI , RedekopWK, van Schie RM et al. Cost–effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. Pharmacogenomics13(12) , 1405–1417 (2012).
   PubMed Web of Science ®Google Scholar
• Verhoef TI , RedekopWK, DarbaJ et al. A systematic review of cost–effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. Pharmacogenomics 11(7) , 989–1002 (2010).
   PubMed Web of Science ®Google Scholar
• Patrick AR , AvornJ, ChoudhryNK. Cost–effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes2(5) , 429–436 (2009).
   PubMed Web of Science ®Google Scholar
• You JH , TsuiKK, WongRS, ChengG. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy. Clin. Pharmacol. Ther.86(5) , 540–547 (2009).
   PubMed Web of Science ®Google Scholar
• Eckman MH , RosandJ, GreenbergSM, GageBF. Cost–effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann. Intern. Med.150(2) , 73–83 (2009).
   PubMed Web of Science ®Google Scholar
• Stolk EA , van Donselaar G, Brouwer WB, Busschbach JJ. Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall. Pharmacoeconomics22(17) , 1097–1107 (2004).
   PubMed Web of Science ®Google Scholar
• Connolly SJ , EzekowitzMD, YusufS et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12) , 1139–1151 (2009).
   PubMed Web of Science ®Google Scholar
• Patel MR , MahaffeyKW, GargJ et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10) , 883–891 (2011).
   PubMed Web of Science ®Google Scholar
• Pink J , LaneS, PirmohamedM, HughesDA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit–harm and economic analyses. BMJ343 , d6333 (2011).
   PubMed Web of Science ®Google Scholar
• Shah SV , GageBF. Cost–effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation123(22) , 2562–2570 (2011).
   PubMed Web of Science ®Google Scholar
• Wallentin L , YusufS, EzekowitzMD et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376(9745) , 975–983 (2010).
   PubMed Web of Science ®Google Scholar

▪ Websites

• Federation of Dutch Anticoagulant clinics; Summary Medical Reports 2010. www.fnt.nl/media/docs/jaarverslagen/Jaarverslag_FNT_Medisch_2010.pdf
   Google Scholar
• Methods and standard prices for economic evaluation studies in healthcare. www.cvz.nl/binaries/live/cvzinternet/hst_content/nl/documenten/losse-publicaties/handleiding-kostenonderzoek-2010.pdf
   Google Scholar
• Dutch drug costs. www.medicijnkosten.nl
   Google Scholar
• Dutch healthcare authority: NZa. DRG tariffs (2011). http://dbc-tarieven.nza.nl/Nzatarieven/top.do
   Google Scholar
• McWilliam A, Lutter R, Nardinelli C. Health care savings from personalizing medicine using genetic testing: the case of warfarin. AEI-Brooking Joint Center for Regulatory Studies Working Paper 06–23 (2006). http://genelex.com/warfarinsavings.pdf?pid=1127
   Google Scholar